Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection

Li, Shu; Chan, Ivan S. F.; Matthews, Holly; Heyse, Joseph F.; Chan, Christina Y.; Kuter, Barbara J.; Kaplan, Karen M.; Vessey, S. J. R.; Sadoff, Jerald C.

doi:10.1097/00006454-200204000-00014

Cited by 114 publications

(82 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[28][29][30][31][32] Specific serum antibody levels for each of these assays was previously shown to correlate with Combination Measles, Mumps, Rubella and Varicella Vaccine (ProQuad ® ) protection against disease; each assay also was shown to correlate with functional antibody assays [33][34][35][36][37] (and unpublished data).…”

Section: Methodsmentioning

confidence: 96%

“…Although the acquisition of any detectable antibodies to varicella (seroconversion) following vaccination has been demonstrated to provide some protection against disease, rates of breakthrough disease have been shown to be significantly lower among children with titers of antibody to varicella ≥5 gpELISA units/mL. 36,41,42 Titers ≥5 gpELISA units/mL have been shown to correlate with long-term protection against breakthrough disease. 36,41,42 For these reasons, antibody response to VZV was evaluated based on postvaccination antibody titers ≥5 gpELISA units/mL.…”

Section: Methodsmentioning

confidence: 99%

“…36,41,42 Titers ≥5 gpELISA units/mL have been shown to correlate with long-term protection against breakthrough disease. 36,41,42 For these reasons, antibody response to VZV was evaluated based on postvaccination antibody titers ≥5 gpELISA units/mL. Antibody persistence rates (measured in Study 3) were defined as the proportion of subjects who maintained a positive response (postvaccination antibody titers above the levels previously defined for antibody response rates) at 1 year among those who were initially seronegative (<1.25 gpELISA units/mL for VZV) and who responded at six weeks postvaccination.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Safety and Immunogenicity of a Combination: Measles, Mumps, Rubella and Varicella Vaccine (ProQuad®)

Kuter

Brown²,

Hartzel³

et al. 2006

Human Vaccines

Self Cite

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 96%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Safety and Immunogenicity of a Combination: Measles, Mumps, Rubella and Varicella Vaccine (ProQuad®)

Kuter

Brown²,

Hartzel³

et al. 2006

Human Vaccines

Self Cite

View full text Add to dashboard Cite

“…They are sensitive enough to detect low antibody levels after vaccination, and have been used to evaluate the level of protection [407] : In one study, 95% of the vaccinated subjects had a gpELISA value of ≥ 5 U/ mL six weeks after immunisation, whereas those with values of < 5 were at three times greater risk of developing BV [413] . However, these tests were not easy to find [30] .…”

Section: Gpelisamentioning

confidence: 99%

Microbiology laboratory and the management of mother-child varicella-zoster virus infection

Paschale

Clerici

2016

WJV

View full text Add to dashboard Cite

Varicella-zoster virus, which is responsible for varicella (chickenpox) and herpes zoster (shingles), is ubiquitous and causes an acute infection among children, especially those aged less than six years. As 90% of adults have had varicella in childhood, it is unusual to encounter an infected pregnant woman but, if the disease does appear, it can lead to complications for both the mother and fetus or newborn. The major maternal complications include pneumonia, which can lead to death if not treated. If the virus passes to the fetus, congenital varicella syndrome, neonatal varicella (particularly serious if maternal rash appears in the days immediately before or after childbirth) or herpes zoster in the early years of life may occur depending on the time of infection. A Microbiology laboratory can help in the diagnosis and management of mother-child infection at four main times: (1) when a pregnant woman has been exposed to varicella or herpes zoster, a prompt search for specific antibodies can determine whether she is susceptible to, or protected against infection; (2) when a pregnant woman develops clinical symptoms consistent with varicella, the diagnosis is usually clinical, but a laboratory can be crucial if the symptoms are doubtful or otherwise unclear (atypical patterns in immunocompromised subjects, patients with post-vaccination varicella, or subjects who have received immunoglobulins), or if there is a need for a differential diagnosis between varicella and other types of dermatoses with vesicle formation; (3) when a prenatal diagnosis of uterine infection is required in order to detect cases of congenital varicella syndrome after the onset of varicella in the mother; and (4) when the baby is born and it is necessary to confirm a diagnosis of varicella (and its complications), make a differential diagnosis between varicella and other diseases with similar symptoms, or confirm a causal relationship between maternal varicella and malformations in a newborn. Core tip: Although varicella during pregnancy is infrequent and congenital varicella syndrome (CVS) is rare, every available means should be used to prevent and diagnose them. Microbiology laboratories can be crucial in these situations: Evaluating a mother's immune status with sensitive and specific tests for the detection of antibodies; allowing a rapid diagnosis with molecular biology tests when a clinical manifestation may be due to different etiologies; following pregnant women with varicella for the prenatal diagnosis of CVS with close collaboration between molecular biology investigators and specialists in imaging diagnostics.De Paschale M, Clerici P. Microbiology laboratory and the management of mother-child varicella-zoster virus infection. World

show abstract

“…Titre specifičnih protiteles se določa z glikoproteinskim testom ELISA (gp-ELISA) in pokazalo se je, da se pri otrocih, ki imajo titre višje od 5 enot/ml, značilno zmanjša tveganje, da zbolijo za noricami v primerjavi s tistimi z nižjimi titri. Ta vrednost tako velja za zaščitno, ki pa jo po cepljenju z enim odmerkom cepiva doseže le 86 % otrok (29). Tako lahko kar pri 24 % cepljenih otrok z enim odmerkom cepiva govorimo o primarni odpovedi cepljenja.…”

unclassified

Vaccinating children against varicella: are two doses of vaccine necessary?

Učakar¹,

Sočan²

2012

Slovenian Journal of Public Health

View full text Add to dashboard Cite

Varicella is a mild childhood disease. Serious UVODVirus Varicela zoster (VZV) je herpesvirus, ki ob prvi okužbi povzroča norice. Po okužbi ostane latentno prisoten v senzornih ganglijih in se pri približno 30 % ljudeh reaktivira, kar se odrazi kot Herpes zoster (pasavec). Norice so običajno blaga otroška bolezen. Resni zapleti, kot so prizadetost osrednjega živčnega sistema (meningitis, meningoencefalitis, cerebelarna ataksija), pljučnica, sekundarne bakterijske okužbe kože in smrt, so redki. Zapleti so pogostejši pri dojenčkih, odraslih in osebah z oslabljenim imunskim sistemom. VZV je zelo nalezljiv, prenaša se po zraku (aerogeno). Osebe brez zaščitnih protiteles se ob stiku okužijo in zbolijo v 61-100 %. Bolezen se pojavlja po vsem svetu in je endemična v večini populacij. Lahko Unauthenticated Download Date | 5/12/18 4:50 AM

show abstract

Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection

Cited by 114 publications

References 13 publications

Safety and Immunogenicity of a Combination: Measles, Mumps, Rubella and Varicella Vaccine (ProQuad®)

Safety and Immunogenicity of a Combination: Measles, Mumps, Rubella and Varicella Vaccine (ProQuad®)

Microbiology laboratory and the management of mother-child varicella-zoster virus infection

Vaccinating children against varicella: are two doses of vaccine necessary?

Contact Info

Product

Resources

About